This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -14.62% and -9.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
by Zacks Equity Research
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
by Zacks Equity Research
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
by Zacks Equity Research
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
by Zacks Equity Research
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.94% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
by Zacks Equity Research
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -5.20% and -5.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?
by Zacks Equity Research
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Factors Expected to Influence Qorvo (QRVO) in Q4 Earnings
by Zacks Equity Research
Qorvo's (QRVO) expanding portfolio of 5G and GaN solutions hold promise.
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide updates on the pipeline, when it reports first-quarter 2019 results on May 2.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Defying the Medicare-for-All Scare
by Swarup Gupta
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
by Zacks Equity Research
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.